Aethlon Medical, Inc. Announces Exercise of All Outstanding Pre-Funded Warrants

Key Points for Investors:

• All previously outstanding pre-funded warrants have been exercised by the holders.
• Shares outstanding: As a result, Aethlon Medical, Inc. now has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026.
• Ticker Symbol: AEMD
• Exchange: Nasdaq Capital Market
• Emerging Growth Company Status: The company is not an emerging growth company.
• Management: The filing was signed by James B. Frakes, Chief Executive Officer and Chief Financial Officer, on March 17, 2026.

What Shareholders Need to Know

The exercise of all outstanding pre-funded warrants is a significant event for shareholders and potential investors. This development means the company has converted all of these warrants into common shares, increasing the number of shares outstanding to 1,569,110. The completion of these exercises eliminates the overhang of pre-funded warrants, which can be a source of uncertainty and could have previously affected the company’s capital structure.

• Share Dilution: The conversion of warrants into common stock results in an increase in shares outstanding, which may dilute existing shareholders. However, this also means the company has received the proceeds from the warrant exercises, potentially strengthening its cash position.
• Capital Structure Certainty: With no pre-funded warrants remaining, the potential for further dilution from these instruments has been eliminated, providing increased transparency regarding the company’s equity base.
• Potential Impact on Share Price: The market may react to the removal of warrant overhang and the increased share count. While dilution is typically seen as negative, the completed conversion and elimination of warrants could also be interpreted positively as it reduces uncertainty.

Additional Details

• No Written Communications or Soliciting Material: The filing is not intended to satisfy obligations under Rule 425 (written communications), Rule 14a-12 (soliciting material), Rule 14d-2(b) or Rule 13e-4(c) (pre-commencement communications). This indicates the filing is solely for disclosure of the warrant exercise and not associated with a merger, tender offer, or other extraordinary transaction.
• Security Details: The company’s common stock trades on the Nasdaq Capital Market under the symbol AEMD, with a par value of \$0.001 per share.

Conclusion

The exercise of all pre-funded warrants and the resulting increase in outstanding shares is a material event that shareholders and investors should note. This action removes a source of potential dilution and uncertainty from the company’s capital structure. Investors should consider how the increased share count and warrant conversion proceeds may impact the company’s financials and market perception.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions. The author and publisher are not responsible for any actions taken based on the information provided above.

View AETHLON MEDICAL INC Historical chart here